Small Molecule CDMO Market: By Product (Small Product API and Small Molecule Drug Product [Oral solid dose, Semi-Solid Dose, Liquid Dose, and Others]), By Phase (Preclinical, Clinical, and Commercial), By Customer Type (Pharmaceuticals and Biotechnology), By Therapeutic Area (Cardiovascular Diseases, Oncology, Respiratory Disorders, Neurology, Metabolic Disorders, Infectious Diseases, and Others) and Geography

Small Molecule CDMO Market size was valued at USD 40.6 billion in 2023 and projected to reach USD 74.5 billion by 2030, growing at a 6.4% CAGR from 2024 to 2030. The market of CDMO small molecule has involved only the development of production of molecule drugs and is predicted to increase significantly. Small molecule CDMO companies observed an overall increase in market revenue by 30% in the year 2021, large molecule market has grown comparatively less. The increasing spending on R&D activities and growing demand for small molecules in the market, rising incidence of cardiovascular diseases, respiratory disorders, and other age-related problems are the major factor that drives the market growth. COVID-19 has impacted market growth, during the pandemic a greater number of CDMO initiatives to meet pharmaceutical targets.

The growing healthcare spending escalates the demand for small molecule CDMO, Pharmaceutical companies are focused on core competencies to allow outsourcing activities for manufacturing and development, and CDMO provides wide opportunities for manufacturing facilities. The CDMO market covers 60% of revenue share in manufacturing activities, and the availability of an abundance of small molecule manufacturers hinders the quality issues associated with products which hamper the market growth. The small molecule CDMOs impacted on both drug production and biopharmaceutical products, the companies are consolidating their supplier base and prefer to work with CDMOs and offer various services across drug substances and manufacturing which is the ongoing trend in the market. Geographically, North America held a significant market share in 2022 showing steady growth in the market. Asia Pacific held a major market share in the historic years, and it is predicted to dominate the market in the forecast years.

Small Molecule CDMO Market Key Developments:

• In April 2022, Novasep, a Lyon, France-based CDMO of APIs and antibody-drug conjugates, and PharmaZell, a Raubling, Germany-based CDMO of small-molecule APIs get merged this strategic merger creates a technology-driven, leading CDMO and API manufacturer